Some theoretical implications from a CNS stimulation model of psychosis were tested by analysing the response patterns of schizophrenic (N = 34), affective disorder patients (N = 18), schizoid personality disorder patients (N = 9), neurotic patients (N = 9) and normal controls (N = 34) on a visual two-choice task with reinforcement. The subjects were required to press a left and right button in order to cause a cross (+) to appear on the monitor screen above one of the buttons. Certain subsequences of right and left presses were required in order for the cross to appear, and a coin-reinforcement was delivered on a variable-ratio schedule with respect to the cross condition. An analysis of structured responding in categories: one-side greater than 6, switching (RLRL), 2-1 switching (RRL) and double alternations (RRLL), revealed that the schizophrenic and affective disorder patients were significantly more perseverative in these response categories than normal controls, schizoid or neurotic patients. The last three subject groups were not significantly different from each other. The majority of the schizophrenics and all four manic patients showed the highest percentage of responding in one sided responses greater than 6, switching and 2-1 switching. Normal control subjects showed more varied response patterns with responses in double, triple and quadruple alternations and other combinations. The results are seen to support a CNS stimulation, behavioral competition model of psychosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-3956(88)90035-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of tonsillectomy on clinical manifestations in Familial Mediterranean fever.
Int J Pediatr Otorhinolaryngol
January 2025
Otorhinolaryngology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; Medicine and Surgery Program, Menoufia National University, Menoufia, Egypt. Electronic address:
Purpose: Familial Mediterranean fever (FMF) is the most prevalent genetic autoinflammatory disease worldwide. There are several novel advancements in pathophysiology, genetic testing, diagnosis, comorbidities, disease-related damage, and treatment strategies. This study aimed to assess the effect of tonsillectomy on FMF disease severity and activity.
View Article and Find Full Text PDFBarriers and Facilitators of User Engagement With Digital Mental Health Interventions for People With Psychosis or Bipolar Disorder: Systematic Review and Best-Fit Framework Synthesis.
JMIR Ment Health
January 2025
Division of Psychology and Mental Health, University of Manchester, Manchester, United Kingdom.
Background: Digital mental health interventions (DMHIs) to monitor and improve the health of people with psychosis or bipolar disorder show promise; however, user engagement is variable, and integrated clinical use is low.
Objective: This prospectively registered systematic review examined barriers and facilitators of clinician and patient engagement with DMHIs, to inform implementation within real-world settings.
Methods: A systematic search of 7 databases identified empirical studies reporting qualitative or quantitative data about factors affecting staff or patient engagement with DMHIs aiming to monitor or improve the mental or physical health of people with psychosis or bipolar disorder.
Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.
J Clin Psychiatry
January 2025
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.
There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.
View Article and Find Full Text PDFEfficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFSynopsis of the 2023 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline for the Management of Bipolar Disorder.
J Clin Psychiatry
January 2025
Department of Veterans Affairs, Washington, DC.
The US Department of Veterans Affairs (VA) and Department of Defense (DOD) Work Group revised the 2013 VA/DOD Clinical Practice Guideline (CPG) for the Management of Bipolar Disorder (BD). This paper reviews the 2023 CPG and its development process, including how recommendations were made for evidence-based treatment in BD. Subject experts and key stakeholders developed 20 key questions and reviewed the published literature after a systematic search using the PICOTS (population, intervention, comparator, outcomes, timing of outcomes measurement, and setting) method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!